Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Leukemia, Myelomonocytic, Chronic 3Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11fludarabine 11Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 9Melphalan 8Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Azacitidine 5Filgrastim 4venetoclax 3Cord Blood Stem Cell Transplantation 3Biopsy 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Methotrexate 2Injections 2Hematopoietic Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporins 2Clofarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × cedazuridine × 1 year × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡